The Chinese company also gets commercialisation rights to three already-marketed cancer drugs, as well as co-development rights to 20 candidates in its oncology pipeline, while Amgen gets to ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

With one of the largest oncology research teams in the industry ... product revenues were positively impacted by growth from ...

Ms. Eastland is an accomplished biopharmaceutical executive with substantial leadership experience operating late-stage oncology companies ... traded biotechnology companies including Dendreon and ...

Shortly after Amgen unveiled its $1.9 billion alliance ... in Sanofi licensing in a first drug candidate in 2019 for oncology and inflammatory diseases and – given the scale of the expanded ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...

Aptose Biosciences Inc. ("Aptose" or the "Company") , a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...